Ruka hadi maudhui makuu

Condition · 1 treatment path

Castration-Resistant Prostate Cancer

Castration-resistant prostate cancer is prostate cancer that keeps growing despite very low testosterone levels from hormone therapy. It usually develops after years of initial hormone treatment.

Severe
Request opinion View roster

Send your imaging + plan. Board-reviewed opinion in 5–10 working days.

Ilisasishwa mwisho: Jinsi tunavyokusanya na kukagua taarifa

Linear accelerator used for radiotherapy in a cancer treatment room
Treatment paths
1Treatment paths
Specialties
2Specialties
Typical severity
SevereTypical severity

About castration-resistant prostate cancer

What to know

It is recognised by a rising PSA blood test or by new spread on bone scans, PET-PSMA or CT scans, sometimes with bone pain, tiredness or urinary symptoms. Doctors check testosterone is truly at castrate level and test for where the cancer has spread. Though serious, there are several treatments that can control it for a period.

Treatment includes newer hormone drugs such as abiraterone and enzalutamide, taxane chemotherapy, radium-223 for bone spread, and radioligand therapy such as lutetium-PSMA for suitable patients. PARP inhibitors are used for those with BRCA changes. Bone-protecting medicines and pain control support quality of life. Treatment abroad is sometimes considered for access to nuclear medicine therapies or clinical trials.

Pre-flight workup

Tests to have already done

  • Recent PSA values with dates, testosterone level confirming castrate range, and PSA trend since starting hormone therapy.
  • Imaging: bone scan, CT or PSMA PET-CT, showing whether disease is in bones, nodes or organs.
  • A full list of previous treatments with dates: surgery, radiotherapy, hormone therapy, abiraterone, enzalutamide, docetaxel.
  • Biopsy pathology, Gleason grade and, where available, tumour genetic results such as BRCA1/2 or other repair-gene testing.
  • Blood tests: blood count, kidney and liver function, calcium, alkaline phosphatase, and bone density or bone-health history.

Second opinion

When to get a second look

  • You have progressed on one hormone drug and are unsure what sequence of further treatments is best.
  • Genetic testing of the tumour or germline has not been done, and might open targeted options.
  • You have bone pain and have not been assessed for bone-protecting therapy or radioligand treatment.

Talking to your doctor

Questions to ask

  1. What are my disease sites now, and has it spread to bones or organs?
  2. Which treatments have I not yet tried, and in what order do you advise them?
  3. Should my tumour be tested for BRCA or other gene changes, and PSMA scanning?
  4. What are the side effects and how will you monitor me?
  5. How do I manage bone health and pain?

Outlook

Realistic prognosis

Castration-resistant prostate cancer is generally not curable, but several treatments, used in sequence, can control it for months to years and relieve symptoms. Outlook depends on how far the disease has spread, PSA behaviour, previous therapies, fitness and gene changes that allow targeted treatment. Bone-protecting medicines and pain control help quality of life.

01 · Specialties

Specialties that treat Castration-Resistant

Specialists Doctors who treat castration-resistant prostate cancer Cross-hospital roster across 2+ relevant specialties. View roster

Diagnostic workup

Before you pick a hospital, get the workup right

Severe — workup typically within 48–72 hours

Picking the right treatment is downstream of a complete diagnosis. Skip steps here and the destination surgeon usually re-orders them anyway — at higher cost and another week on the ground.

  1. Confirm the diagnosis on imaging or labs

    For castration-resistant prostate cancer, plan on the workup your home doctor would order anyway — typically a recent specialist consult plus the imaging / labs the destination team will need to quote accurately. Anything older than 90 days usually gets re-done.
  2. See a oncology specialist locally first

    An in-person clinical exam at home — even a single consult — costs little and dramatically improves the destination plan. Bring back: written impression, recommended procedure, surgical-risk class, and any contra-indications.
  3. Send us the file for a free second opinion

    Two surgeons in our medical panel review the workup independently. They tell you whether they'd operate, watch, or refer — even if that means recommending against travel.
  4. Pick a path with timeline + cost in writing

    Once a treatment is the right call, we line up 2–3 hospital options with itemized quotes, surgeon profiles, and a travel timeline. You hold the file — switch hospitals or step away at any point.

03 · Treatment paths

Treatment options

All treatments

Where to be treated

Castration-Resistant Prostate Cancer treatment by destination

Get a panel match

04 · FAQ

Common questions about castration-resistant prostate cancer

Is castration-resistant prostate cancer the end of treatment options?

No. Several options remain, including newer hormone drugs, chemotherapy, radium-223, PSMA radioligand therapy and PARP inhibitors for selected patients. The order depends on prior treatments and tumour features.

Does it mean the cancer has spread?

Not necessarily, but many cases involve spread to bones or nodes. Scans, including PSMA PET-CT where available, show the extent.

Why is genetic testing recommended?

Tumour or germline changes, such as BRCA1/2, may qualify you for targeted treatment and also matter for relatives.

Can I travel during treatment?

Often yes between treatment cycles if blood counts and general health allow. Plan for supplies of tablets and keep records of your treatments.

Clinical context

Working up castration-resistant prostate cancer properly

A condition like castration-resistant prostate cancer is rarely well-served by jumping straight to treatment shopping. The sequence below is what a oncology specialist would expect to see completed — and the absence of any step is the right cue to delay travel decisions.

Diagnostic workup, in sequence

  1. First-line clinical assessment

    History, physical exam, and risk-factor review by a senior generalist or oncology specialist. Symptoms list, family history, prior workup notes, and current medication list should travel with the patient.

  2. Standard imaging + labs

    Baseline blood work, condition-specific imaging (ultrasound / X-ray / MRI / CT — depending on indication), and ECG / pulmonary function as relevant. Bring digital copies of any prior imaging — saves repeat scans and the cost that goes with them.

  3. Specialist diagnostic workup

    Procedure-specific tests — biopsy, cardiac catheterisation, endoscopy, or genetic / molecular profiling depending on the suspected diagnosis. Done at the centre that will treat, ideally, so results integrate cleanly into the treatment plan.

  4. Multidisciplinary review (where indicated)

    Cancer, complex cardiac, transplant, and rare-disease cases should be reviewed by a multidisciplinary panel — surgical, medical, imaging, and pathology — before any treatment commits. Single-discipline plans for complex disease are a quality red flag.

When to escalate urgently

  • Acute worsening of established symptoms — sudden chest pain, shortness of breath at rest, neurological deficit, severe bleeding, persistent high fever.
  • Loss of consciousness, severe persistent vomiting, or any focal neurological event.
  • Symptoms in the early hours of onset that fit a time-sensitive treatment window (stroke, MI, sepsis) — every hour costs outcome.
  • If you are travelling internationally for treatment and develop these symptoms in transit, divert to the nearest emergency department; do not wait to reach the planned destination.

Before you book international travel

  • Confirm your specific diagnosis is fully worked up before you commit to a treatment plan abroad. Travelling for the workup is fine; travelling for treatment without the workup done is not.
  • Get your case reviewed remotely by the destination centre's team before you book flights — credible international patient programs review imaging + reports before they confirm the surgical plan.
  • Bring a digital + physical copy of your full medical record: imaging on USB drive in DICOM format, labs in PDF, current medication list with dosages, allergies, and any prior surgical reports.
  • Plan for longer recovery + post-discharge therapy continuation before you fly — the surgery itself is rarely the bottleneck.
  • Confirm that follow-up imaging and any necessary in-person reviews can be done at home — a treatment plan that requires repeat international trips is more burdensome (and more expensive) than the headline procedure.
Jinsi ukurasa huu ulivyoandaliwa

Mbinu na viwango vya uhariri

This castration-resistant prostate cancer overview is written by the editorial team from published Oncology sources and lists 1 treatment options offered by hospitals on our network. The page shows its last-updated date. Clinical descriptions are editorial — your treating clinician confirms what's right for your specific case.

  1. Taarifa za hospitali. Maelezo ya hospitali yanakusanywa kutoka vyanzo vya umma na tovuti za hospitali. Uidhinishaji (JCI, NABH na mengine) huonyeshwa pale tulipo na rekodi. Daima omba hospitali cheti chake cha sasa.
  2. Sifa za madaktari. Sifa, utaalamu na wasifu hutoka wasifu wa daktari hospitalini. Leseni hukaguliwa kwenye rejista ya baraza la kitaifa la madaktari tu pale wasifu unapoonyesha alama ya "Leseni imehakikiwa" yenye tarehe.
  3. Bei. Viwango vya bei ni vya kukadiria, vimekusanywa kutoka orodha za bei na vifurushi vya hospitali na huonyeshwa na tarehe ya mwisho ya kusasishwa. Unacholipa ni kile kilichoandikwa kwenye nukuu ya hospitali.
  4. Maandishi ya kitabibu. Imeandikwa na timu ya wahariri ya Medcasts kutoka vyanzo vya kliniki vilivyochapishwa. Isipokuwa ukurasa umetaja mhakiki kwa jina, haujakaguliwa na daktari.
  5. Uhuru. Hospitali haziwezi kulipa ili kubadilisha nafasi yao kwenye kurasa zetu.
Vyanzo vya taarifa za ukurasa huu
Peer-reviewed clinical guidelines (NCCN, ESMO, ESC, AHA, NICE — by indication)WHO ICD-11 condition classificationNational medical society treatment protocolsJCI accreditation registry

Castration-Resistant Prostate Cancer

Continue evaluating castration-resistant prostate cancer care

Condition overview is one entry. These hubs route the same care decision via specialty, surgeon, treatment, and destination — including the doctors actively treating castration-resistant prostate cancer.

Hatua inayofuata · Castration-Resistant Prostate Cancer

Free second opinion on your Castration-Resistant case.

Share imaging and the current plan. Multidisciplinary board returns a written opinion within 5–10 working days — no obligation to travel.

Pata makadirio ya bei bureMakadirio ya kina kutoka hospitali zilizoidhinishwa, bila malipo Maoni ya pili ya daktari bureMtaalamu anapitia ripoti zako Ongea na mratibuWhatsApp, barua pepe au simu